Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 701–800 of 2,517
The p53 mutation “gradient effect” and its clinical implications
Zambetti, G. P. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21217 · Cited by 71
TP53 and mutations in human cancer.
Szymańska, K., & Hainaut, P. L. (2003) · Acta Biochimica Polonica · doi:10.18388/abp.2003_3731 · Cited by 71
“Thus, substitution of these residues results in a protein with decreased affinity for DNA, which has lost the capacity to suppress proliferation (Cho et al., 1994).”
BackgroundKlein, C., Georges, G., Künkele, K.-P., Huber, R., Engh, R. A., & Hansen, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103801200 · Cited by 71
Activity of paclitaxel liposome formulations against human ovarian tumor xenografts
Sharma, A., Mayhew, E. G., Bolcsak, L. E., Cavanaugh, C., Harmon, P. A., Janoff, A. S., & Bernacki, R. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970328)71:1 · Cited by 136
Turrell, F. K., Kerr, E. M., Gao, M., Thorpe, H., Doherty, G. J., Cridge, J., Shorthouse, D., Speed, A., Samarajiwa, S., Hall, B. A., et al. (2017) · Genes & Development · doi:10.1101/gad.298463.117 · Cited by 71
Extensive Post-translational Modification of Active and Inactivated Forms of Endogenous p53
DeHart, C. J., Chahal, J. S., Flint, S. J., & Perlman, D. H. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.030254 · Cited by 70
“Arg 174 and Arg 181 have been implicated in maintaining the folded structure of the p53 monomer (128), Arg 202 contributes to dimer structural stability (129), Arg 280 is essential for DNA binding (128, 130), and Arg 342 is necessary for p53-dependent transcription (131).”
BackgroundInhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 70
“6 Also located within the carboxyl terminus are nuclear localization signals (NLS), and there is a nuclear export sequence located in the oligomerization domain and activation domain (Cho et al., 1994; Dang and Lee, 1989; Hainaut et al., 1997).”
BackgroundKoutsodontis, G., Vasilaki, E., Chou, W.-C., Papakosta, P., & Kardassis, D. (2005) · Biochemical Journal · doi:10.1042/bj20041980 · Cited by 70
p53 Mutation in Squamous Cell Carcinomas from Psoriasis Patients Treated with Psoralen + UVA (PUVA)
Nataraj, A. J., Wolf, P., Cerroni, L., & Ananthaswamy, H. N. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12319764 · Cited by 76
Fanzo, J. C., Reaves, S. K., Cui, L., Zhu, L., Wu, J. Y. J., Wang, Y. R., & Lei, K. Y. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.3.c751 · Cited by 69
“These loops are connected by a zinc atom bound to cysteine and histidine amino acids (5).”
BackgroundCasso, D. J., & Beach, D. (1996) · Molecular and General Genetics MGG · doi:10.1007/s004380050259 · Cited by 78
“The p53 DNA binding domain contains a Zn 2÷ ion tetrahedrally coordinated between two cysteines (at codons 242 and 176) and two histidines (Hainault and Milner 1993b; Cho et al. 1994).”
BackgroundJohansson, B., Mertens, F., & Mitelman, F. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199607)16:3<155::aid-gcc1>3.0.co;2-y · Cited by 169
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Oncogenic Intra-p53 Family Member Interactions in Human Cancers
Ferraiuolo, M., Di Agostino, S., Blandino, G., & Strano, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00077 · Cited by 69
Human tumor suppressor p53 and DNA viruses
Collot‐Teixeira, S., Bass, J., Denis, F., & Ranger‐Rogez, S. (2004) · Reviews in Medical Virology · doi:10.1002/rmv.431 · Cited by 69
“Most p53 mutations identified in tumors occur at sites located on the central core DNA-binding domain [10].”
Wang, Y., Zhu, X., Wu, M., Xia, N., Wang, J., & Zhou, F. (2009) · Analytical Chemistry · doi:10.1021/ac9014269 · Cited by 71
Friedler, A., DeDecker, B. S., Freund, S. M. V., Blair, C., Rüdiger, S., & Fersht, A. R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.12.005 · Cited by 69
Molecular Dynamics Simulations of p53 DNA-Binding Domain
Lu, Q., Tan, Y.-H., & Luo, R. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp0742261 · Cited by 68
Predicting Positive p53 Cancer Rescue Regions Using Most Informative Positive (MIP) Active Learning
Danziger, S. A., Baronio, R., Ho, L. S., Hall, L., Salmon, K. A., Hatfield, G. W., Kaiser, P., & Lathrop, R. H. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000498 · Cited by 90
“Modeled mutant proteins were produced in silico using the B chain of the wildtype p53 core domain crystal structure (PDB ID: 1TSR) [33].”
MethodToxic effects of metal oxide nanoparticles and their underlying mechanisms
Wang, Y., Ding, L., Yao, C., Li, C.-C., Xing, X., Huang, Y., Gu, T., & Wu, M. (2017) · Science China Materials · doi:10.1007/s40843-016-5157-0 · Cited by 77
Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting Protein Kinase-2 Knockdown
Puca, R., Nardinocchi, L., Gal, H., Rechavi, G., Amariglio, N., Domany, E., Notterman, D. A., Scarsella, M., Leonetti, C., Sacchi, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6776 · Cited by 69
“The X-ray crystallography elucidated the DNA-binding domain structure of p53 and shows the importance of zinc atom in stabilizing this structure ( 13 ).”
BackgroundPyrrolidine Dithiocarbamate Prevents p53 Activation and Promotes p53 Cysteine Residue Oxidation
Wu, H.-H., & Momand, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.18898 · Cited by 68
Finding function through structural genomics
Shapiro, L. S., & Harris, T. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00064-6 · Cited by 73
Diffusion NMR Spectroscopy: Folding and Aggregation of Domains in p53
Dehner, A., & Kessler, H. (2005) · ChemBioChem · doi:10.1002/cbic.200500093 · Cited by 80
PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
“Residue 280 in human p53, corresponding to R277 in mouse p53, is located in the H2 helix domain and makes direct contacts with DNA; substitution of this residue compromises interactions between p53 and DNA [11].”
BackgroundInfluentialNorth, S., el-Ghissassi, F., Pluquet, O., Verhaegh, G. W. C. T., & Hainaut, P. L. (2000) · Oncogene · doi:10.1038/sj.onc.1203413 · Cited by 72
“The protein contains a cysteinedependent zinc-binding structure that is reversibly altered by thiol oxidation (Cho et al., 1994).”
BackgroundSchmitz, R., Renné, C., Rosenquist, R., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403841 · Cited by 68
Heinzel, P. A., Balaram, P., & Bernard, H. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961115)68:4<428::aid-ijc5>3.0.co;2-2 · Cited by 70
The p53 tumour suppressor gene: a mediator of a G1 growth arrest and of apoptosis
Yonish-Rouach, E. (1996) · Cellular and Molecular Life Sciences · doi:10.1007/bf01920109 · Cited by 73
DNA damage, p53 and anticancer therapies
Milner, J. (1995) · Nature Medicine · doi:10.1038/nm0995-879 · Cited by 67
Henriksen, J. M., Ågesen, T. H., Mælandsmo, G. M., Lothe, R. A., Myklebost, O., & Forus, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206671 · Cited by 65
“The alteration of codon 286, resulting in Glu-to-Lys, would probably disrupt the structure of the core domain that binds specific DNA sequences (Cho et al., 1994).”
BackgroundDifferential apoptosis markers in human keloids and hypertrophic scars fibroblasts
Felice, B. D., Garbi, C., Santoriello, M., Santillo, A., & Wilson, R. R. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0057-x · Cited by 71
“Indeed, the vast majority of p53 mutations involve exons 5 through 8, a highly conserved DNA-binding domain critical for p53 function [19].”
BackgroundWang, G. G., Zhao, Y., Liu, X., et al. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1138 · Cited by 67
“…factors, such as hepatitis B virus, hepatitis C virus, and aflatoxin, and genetic factors, although its precise molecular pathogenesis remains to be elucidated (Cho et al., 1994; Khakoo et al., 1996; Di Bisceglie, 1997; Montesano et al., 1997; Akriviadis et al., 1998; Schafer and Sorrell, 1999).”
BackgroundMarutani, M., Tonoki, H., Tada, M., Takahashi, M., Kashiwazaki, H., Hida, Y., Hamada, J. I., Asaka, M., & Moriuchi, T. (1999) · PubMed · Cited by 76
Somatic mutation theory, DNA repair rates, and the molecular epidemiology of p53 mutations
Holmquist, G. P., & Gao, S. (1997) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(96)00045-2 · Cited by 66
Overview of Protein Structural and Functional Folds
Sun, P. D., Foster, C. E., & Boyington, J. C. (2004) · Current Protocols in Protein Science · doi:10.1002/0471140864.ps1701s35 · Cited by 103
“The first of these families to be examined structurally, p53 tumor supressors (Table 17 .1.6), can bind DNA as a monomer (Cho et al., 1994) .”
BackgroundInfluentialKucab, J. E., Phillips, D. H., & Arlt, V. M. (2010) · FEBS Journal · doi:10.1111/j.1742-464x.2010.07676.x · Cited by 72
Végran, F., Boidot, R., Oudin, C., DeFrain, C., Rebucci, M., & Lizard‐Nacol, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209784 · Cited by 73
“In addition, missense mutations that occur within the L2 and L3 loops (residues 163–195 and 236–251) disrupt its stability (Cho et al., 1994).”
BackgroundStructure of the sporulation‐specific transcription factor Ndt80 bound to DNA
Lamoureux, J. S., Stuart, D. A., Tsang, R. Y., Wu, C. M., & Glover, J. N. M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf572 · Cited by 68
Specific TP53 mutation pattern in radiation-induced sarcomas
Britzen‐Laurent, N., Gibaud, A., Huygue, M., Lefèvre, S.-H., Bras, M. L., Chauveinc, L., Sastre‐Garau, X., Doz, F., Rouïc, L. L.-L., Chevillard, S., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi356 · Cited by 71
Tumours and Tumour-like Lesions of the Liver
Ferrell, L. D., Kakar, S., Terracciano, L., & Wee, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00013-3 · Cited by 74
Nagaich, A. K., Zhurkin, V. B., Sakamoto, H., Gorin, A. A., Clore, G. M., Gronenborn, A. M., Appella, E., & Harrington, R. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14830 · Cited by 66
p53’s Extended Reach: The Mutant p53 Secretome
Pavlakis, E., & Stiewe, T. (2020) · Biomolecules · doi:10.3390/biom10020307 · Cited by 68
Kamaraj, B., & Bogaerts, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134638 · Cited by 64
Solomon, H., Buganim, Y., Pomeraniec, L., Beatus, T., Assia, Y., Kogan-Sakin, I., Madar, S., Goldstein, I., Brosh, R., Kalo, E., et al. (2012) · Journal of Cell Science · doi:10.1242/jcs.099663 · Cited by 65
“The second group includes p53 conformational mutations (e.g. R175, H179), which alter the scaffold that orients the structure of the DNA-binding interface (Cho et al., 1994).”
BackgroundStructural biology of the p53 tumour suppressor
Okorokov, A. L., & Orlova, E. V. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.02.003 · Cited by 65
Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells
Godek, K. M., Venere, M., Wu, Q., Mills, K. D., Hickey, W. F., Rich, J. N., & Compton, D. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1154 · Cited by 74
Okorokov, A. L., Ponchel, F., & Milner, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.19.6008 · Cited by 77
“1Corresponding author Missense point mutations can inactivate p53 and this is the most common genetic event linked with human cancer p53 is able to recognize and bind sites of DNA damage (Cho et al., 1994; Prives, 1994; Hollstein et al., 1996).”
BackgroundUberti, D. L., Lanni, C., Carsana, T., Francisconi, S., Missale, C., Racchi, M., Govoni, S. M., & Memo, M. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.013 · Cited by 67
“Lack of p53 activity could be due essentially to gene mutations, as often occurs in tumours, or post-transcriptional modification both altering p53 tertiary structure and preventing binding to specific DNA sequences [4,20,22,23].”
BackgroundAn apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele.
Nakamura, T., Pichel, J. G., Williams-Simons, L., & Westphal, H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.6142 · Cited by 64
The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage
Okorokov, A. L., Rubbi, C. P., Metcalfe, S. M., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205112 · Cited by 65
“…wild type conformation, but is unable to Oncogene Oncogene interact with sequence-speci®c DNA-targets of p53, and two of the most frequent p53 mutants in human cancer which exhibit either abnormal conformation (R175H) or inability to interact with the p53 consensus site (R273H) (Cho et al., 1994).”
BackgroundInfluentialp53 mutations and chromosome instability in basal cell carcinomas developed at an early or late age.
D’Errico, M., Calcagnile, A. S., Corona, R., Fucci, M., Annessi, G., Baliva, G., Tosti, M. E., Pasquini, P., & Dogliotti, E. (1997) · PubMed · Cited by 79
Structural Evolution and Dynamics of the p53 Proteins
Chillemi, G., Kehrloesser, S., Bernassola, F., Desideri, A., Dötsch, V., Levine, A. J., & Melino, G. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028308 · Cited by 65
“The DBD core domain adopts an immunoglobulin-like b sandwich architecture that provides a scaffold for a DNA-binding surface, consisting of a loop–sheet–helix motif and two loops stabilized by a zinc ion (Cho et al. 1994; Joerger and Fersht 2010).”
BackgroundCognate DNA Stabilizes the Tumor Suppressor p53 and Prevents Misfolding and Aggregation
Ishimaru, D., Ano Bom, A. P. D., Lima, L. M. T. R., Quesado, P. A., Oyama, M. F. C., de Moura Gallo, C. V., Cordeiro, Y., & Silva, J. L. (2009) · Biochemistry · doi:10.1021/bi9003028 · Cited by 64
Khazanov, N., & Levy, Y. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.059 · Cited by 69
Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer
Villiard, É., Brinkmann, H., Moiseeva, O. V., Mallette, F. A., Ferbeyre, G., & Roy, S. (2007) · BMC Evolutionary Biology · doi:10.1186/1471-2148-7-180 · Cited by 67
“The neighboring R175 mediates interactions between the loops that contact the DNA and may stabilize the core structure of the DNA binding domain [61].”
BackgroundDirect influence of the p53 tumor suppressor on mitochondrial biogenesis and function
DONAHUE, R. J., RAZMARA, M., HOEK, J. B., & KNUDSEN, T. B. (2001) · The FASEB Journal · doi:10.1096/fj.00-0262com · Cited by 64
Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53
Süße, S., Janz, C., Janus, F., Deppert, W., & Wiesmüller, L. (2000) · Oncogene · doi:10.1038/sj.onc.1203809 · Cited by 72
“This mutant possesses wild-type p53 conformation (Ory et al., 1994), but is devoid of arginine 273, which contacts the phosphate backbone of DNA according to the crystal structure of p53 bound to double-stranded consensus sequence DNA (Cho et al., 1994).”
BackgroundMurata, J., Tada, M., Iggo, R. D., Sawamura, Y., Shinohe, Y., & Abe, H. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00149-8 · Cited by 64
Cytoplasmic p53 Polypeptide Is Associated with Ribosomes
Fontoura, B. M. A., Atienza, C. A., Sorokina, E. A., Morimoto, T., & Carroll, R. B. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3146 · Cited by 74
“binding domain (residues 364 to 390 in the murine p53 polypeptide) (42, 58) distinct from (i) the DNA binding domain (2, 7, 44, 57), and (ii) the 5.”
BackgroundThe single-stranded DNA end binding site of p53 coincides with the C- terminal regulatory region
Selivanova, G. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.18.3560 · Cited by 64
Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils
Yang, D. S., Saeedi, A., Davtyan, A., Fathi, M., Sherman, M. B., Safari, M. S., Klindziuk, A., Barton, M. C., Varadarajan, N., Kolomeisky, A. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015618118 · Cited by 62
A Novel Function for p53: Regulation of Growth Cone Motility through Interaction with Rho Kinase
Qin, Q., Baudry, M., Liao, G., Noniyev, A., Galeano, J., & Bi, X. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0420-09.2009 · Cited by 63
“…is one of the most prevalent p53 mutations in human cancer mutations; the mutation occurs in the DNA binding domain and belongs to the family of conformational mutants (in contrast to contact site mutants) that inhibit p53 function by altering the structure of the protein (Cho et al., 1994).”
BackgroundPaleček, E., Brázdová, M., Černocká, H., Vlk, D., Brázda, V., & Vojtěšek, B. (1999) · Oncogene · doi:10.1038/sj.onc.1202710 · Cited by 62
“…1996). p53CON consists of two copies of the sequence 5'-PuPuPuC(A/T)(T/A)GPyPyPy-3', separated by 0 ± 13 bp. Three-dimensional models of the tetramerization domain (Arrowsmith and Morin, 1996) and of the core DNA-binding domain (Arrowsmith and Morin, 1996; Cho et al., 1994) are now available.”
BackgroundInfluentialWani, M. A., Zhu, Q., El-Mahdy, M. A., Venkatachalam, S., & Wani, A. A. (2000) · PubMed · Cited by 68
Tumor Suppressor Gene Mutations and Photocarcinogenesis
Ziegler, A., Jonason, A. S., Simon, J., Leffell, D. J., & Brash, D. E. (1996) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1996.tb03064.x · Cited by 61
Krause, M. K., Rhodes, L. D., & Beneden, R. J. V. (1997) · Gene · doi:10.1016/s0378-1119(96)00841-4 · Cited by 62
AMF1 (GPS2) Modulates p53 Transactivation
Peng, Y., Kuo, F., Breiding, D. E., Wang, Y., Mansur, C. P., & Androphy, E. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5913-5924.2001 · Cited by 64
“It is within this central domain that 80 to 90% of the tumor mutations are found ( 12 ).”
BackgroundOrigins and selection of p53 mutations in lung carcinogenesis
Rodin, S. N., & Rodin, A. S. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.08.005 · Cited by 70
Formation and repair of DNA lesions in thep53 gene: Relation to cancer mutations?
Pfeifer, G. P., & Denissenko, M. F. (1998) · Environmental and Molecular Mutagenesis · doi:10.1002/(sici)1098-2280(1998)31:3<248::aid-em6>3.0.co;2-g · Cited by 63
Structural and Drug Targeting Insights on Mutant p53
Gomes, A. S., Ramos, H., Inga, A., Sousa, E., & Saraiva, L. (2021) · Cancers · doi:10.3390/cancers13133344 · Cited by 62
“Next to this hydrophobic area, there are two hydrophilic networks that contribute to its stability, one far from DNA, involving charged residues from the two monomers (specifically R174, E180, R181, and several water molecules), and the second one near to DNA, with a first-shell hydration of the protein surface facing…”
BackgroundInfluentialTP53 in Biology and Treatment of Osteosarcoma
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 70
Rigacci, S., Bucciantini, M., Relini, A., Pesce, A., Gliozzi, A., Berti, A., & Stefani, M. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.122283 · Cited by 64
“Although the solution and x-ray structures of the DNA-binding domain and the tetramerization domain have been determined (6,7), there is a substantial lack of structural and biophysical information on the fulllength protein as well as on N-terminal domain.”
BackgroundWeidman, M. K., Yalamanchili, P., Ng, B., Tsai, W., & Dasgupta, A. (2001) · Virology · doi:10.1006/viro.2001.1215 · Cited by 61
“It functions as a typical sequence-specific transcription activator (Farmer et al., 1992; Kern et al., 1991) that binds as a tetramer (Jeffrey et al., 1995) to four tandem, alternatively inverted copies of a 5-bp consensus sequence (Cho et al., 1994; Halazonetis and Kandil, 1993).”
BackgroundFriedler, A., Veprintsev, D. B., Rutherford, T., von Glos, K. I., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411176200 · Cited by 61
The complex interactions of p53 with target DNA: we learn as we go
Kim, E., & Deppert, W. (2003) · Biochemistry and Cell Biology · doi:10.1139/o03-046 · Cited by 62
“…for the functions of p53 is underscored by the fact that loss of sequencespecific DNA binding (SSDB) impairs p53-dependent growth suppression and is the most characteristic feature of mutant p53 proteins (Cho et al. 1994; Vogelstein et al. 2000; Soussi and Beroud 2001; Bullock and Fersht 2001).”
BackgroundmRTVP-1, a Novel p53 Target Gene with Proapoptotic Activities
Ren, C., Li, L., Goltsov, A. A., Timme, T. L., Tahir, S. A., Wang, J., Garza, L., Chinault, A. C., & Thompson, T. C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3345-3357.2002 · Cited by 62
“The majority of p53 mutations in human tumors have shown decreased sequence-specific DNA binding and transactivation activity (6).”
BackgroundBiochemical and Biophysical Properties of the Core-binding Factor α2 (AML1) DNA-binding Domain
Crute, B. E., Lewis, A. F., Wu, Z., Bushweller, J. H., & Speck, N. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.42.26251 · Cited by 62
Structural diversity of p63 and p73 isoforms
Osterburg, C., & Dötsch, V. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00975-4 · Cited by 70
“The corresponding residue in p53, R248, is the most frequently mutated residue found in cancer cells [103] and makes contacts in the minor groove of the A/T-rich region flanking the core CATG sequence which results in a narrowing of the minor groove [97].”
BackgroundLukman, S., Lane, D. P., & Verma, C. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080221 · Cited by 60
“regardless of the conformational states of L1 [17,38,40].”
Backgroundp53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation
Artigas, N., Gámez, B., Cubillos‐Rojas, M., Sánchez‐de‐Diego, C., Valer, J. A., Pons, G., Rosa, J. L., & Ventura, F. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.113 · Cited by 68
Human Topoisomerase IIα and IIβ Interact with the C-Terminal Region of p53
Cowell, I. G., Okorokov, A. L., Cutts, S. A., Padget, K., Bell, M., Milner, J., & Austin, C. A. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4772 · Cited by 62
Cancer Predisposition, Radiosensitivity and the Risk of Radiation-Induced Cancers. I. Background
Sankaranarayanan, K., & Chakraborty, R. (1995) · Radiation Research · doi:10.2307/3579149 · Cited by 71
MBP1: a novel mutant p53-specific protein partner with oncogenic properties
Gallagher, W. M., Argentini, M., Sierra, V., Bracco, L. P., Debüssche, L., & Conseiller, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202937 · Cited by 60
“…acid (aa) residues within p53 most often targeted by the mutagenic process are thought to be normally involved in either directly contacting DNA or stabilizing the structure of the DNA binding surface, giving rise to the respective terms `contact' and `structural' p53 mutants (Cho et al., 1994).”
BackgroundWang, J., Zhang, Z., Hartman, M., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640402 · Cited by 61
Shimamura, A., & Fisher, D. E. (1996) · PubMed · Cited by 61
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
Traweek, R. S., Cope, B. M., Roland, C. L., Keung, E. Z.-Y., Nassif, E. F., & Erstad, D. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1006959 · Cited by 66
Role of tumor suppressor p53 domains in selective binding to supercoiled DNA
Brázdová, M., Paleček, J., Cherny, D. I., Billová, S., Fojta, M., Pečínka, P., Vojtesek, B., Jovin, T. M., & Palecek, E. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf616 · Cited by 62
“Core domain-containing recombinant plasmid p53(94‐312) was from S. Gorina ( 26 ).”
BackgroundDocking study and free energy simulation of the complex between p53 DNA‐binding domain and azurin
De Grandis, V., Bizzarri, A. R., & Cannistraro, S. (2007) · Journal of Molecular Recognition · doi:10.1002/jmr.840 · Cited by 60
“The initial p53 DBD configuration (shown on the right in Figure 1) was taken from chain B of PDB entry 1TUP, describing the 2.2 Å resolution crystal structure of this domain in complex with a consensus DNA-binding site (Cho et al., 1994).”
BackgroundMethodInfluentialMandić, R., Schamberger, C. J., Müller, J. F., Geyer, M., Zhu, L., Carey, T. E., Grenman, R. A., Dünne, A.-A., & Werner, J. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0378 · Cited by 60
Reactive oxygen species modulate Zn2+-induced apoptosis in cancer cells
Provinciali, M., Donnini, A., Argentati, K., Stasio, G. D., Bartozzi, B., & Bernardini, G. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00830-9 · Cited by 60
New Insights into the Mechanism of Inhibition of p53 by Simian Virus 40 Large T Antigen
Sheppard, H. M., Corneillie, S. I., Espiritu, C., Gatti, A. V., & Liu, X. E. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2746 · Cited by 60
“However, resolution of the crystal structure of a human p53 core domain-DNA complex has localized the region of p53 directly contacted by DNA to three structural elements which include the H2 helix (amino acids [aa] 278 to 286), the L1 loop (aa 112 to 124), and the L3 loop (aa 236 to 251) (7).”
BackgroundPoele, R. T., Okorokov, A. L., & Joel, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202961 · Cited by 60
“The cell lines HT29, carrying mutant p53 (R273H) and SW48, carrying p53 mutant R248W, did not respond to DRB treatment by undergoing apoptosis.”
BackgroundMethodInfluentialCostello, R. T., Mallet, F., Sainty, D., Maraninchi, D., Gastaut, J.-A., & Olive, D. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<90::aid-immu90>3.0.co;2-5 · Cited by 81
Abdel‐Fattah, R., Challen, C., Griffiths, T. R. L., Robinson, M., Neal, D. E., & Lunec, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.371 · Cited by 60
“Thus, these two hot spot residues also appear to play a critical role in stabilizing the structure of the DNA-binding surface of TP53 (Cho et al, 1994).”
BackgroundInfluentialMalčíková, J., Pavlová, Š., Vonková, B., Radová, L., Plevová, K., Kotašková, J., Pál, K., Dvořáčková, B., Ženatová, M., Hynšt, J., et al. (2021) · Blood · doi:10.1182/blood.2020009530 · Cited by 65
“DNAbindingmotifasclassifiedby Cho et al.(48) #Frequency of mutations categorized according to Seshat(28): frequent (very frequent1frequent) vs not frequent1rare1unique1never identified.”
Su, Z., Kon, N., Yi, J., Zhao, H., Zhang, W., Tang, Q., Li, H., Kobayashi, H. H., Li, Z., Duan, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00532-z · Cited by 73
Illuminating p53 function in cancer with genetically engineered mouse models
Garcia, P. B., & Attardi, L. D. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2013.12.014 · Cited by 59
From local to global changes in proteins: a network view
Vuillon, L., & Lesieur, C. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2015.02.015 · Cited by 62
The p53 Core Domain Is a Molten Globule at Low pH
Ano Bom, A. P. D., Freitas, M. S., Moreira, F. S., Ferraz, D., Sanches, D., Gomes, A. M. O., Valente, A. P., Cordeiro, Y., & Silva, J. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075861 · Cited by 60
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.